AN OVERVIEW OF THE RESISTANCE MECHANISMS OF CANDIDA ALBICANS AND THE TREATMENT OF RECURRENT CANDIDIASIS
DOI:
https://doi.org/10.47820/recima21.v4i3.2867Keywords:
recurrent vulvovaginal candidiasis, treatment, candidiasis, vaginosis.Abstract
Recurrent candidiasis, or recurrent vulvovaginal candidiasis (RVC), is a condition that affects thousands of women worldwide every year. The most characteristic symptoms are known to be itching, vulvar pain, dysuria, and leukorrhea, and recurrence is determined when at least four different episodes of vulvovaginal candidiasis occur within a 12-month period. Several factors may influence its recurrence, including genetic, biological, or behavioral causes. Although CVR is a very common disease in the population, it is also known for its deleterious complications if not treated properly, including infertility, premature birth, miscarriage, and other infectious diseases. The classic recommended treatment for CVR is the use of antifungals, however, an increase in resistance to these drugs has been observed in recent years. In response, new therapeutic approaches have been tested, with vaccines against Candida ssp., drugs based on biofilm eradication, nanotechnology and peptides, lactobacilli and immunotherapy, as possible alternatives to exclusive reliance on antifungals. This study aims to analyze the therapeutic methods available for RVC through a review of existing literature, with the purpose of developing an overview of the current management and news about the treatment of recurrent vulvovaginal candidiasis, to elucidate the medical practice before this frequent complaint in medical offices, both clinical and gynecological.
Downloads
References
ALVENDAL C, MOHANTY S, BOHM-STARKE N, BRAUNER A. Anti-biofilm activity of chlorhexidine digluconate against Candida albicans vaginal isolates. PLoS One. 2020;15(9):e0238428.
BRAND SR, DEGENHARDT TP, PERSON K, et al. A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 2018;218(6):624.
DAVAR R, NOKHOSTIN F, EFTEKHAR M, SEKHAVAT L, BASHIRI ZADEH M, SHAMSI F. Comparing the Recurrence of Vulvovaginal Candidiasis in Patients Undergoing Prophylactic Treatment with Probiotic and Placebo During the 6 Months. Probiotics Antimicrob Proteins. 2016;8(3):130-133.
DE ABREU LCL, TODARO V, SATHLER PC, DA SILVA LCRP, DO CARMO FA, COSTA CM et. Al. Development and Characterization of Nisin Nanoparticles as Potential Alternative for the Recurrent Vaginal Candidiasis Treatment. AAPS Pharm SciTech, 2016. 17(6): 1421-1427.
DECHERF A, DEHAY E, BOYER M, CLÉMENT-ZIZA M, RODRIGUEZ B, LEGRAIN-RASPAUD S. Recovery of Saccharomyces cerevisiae CNCM I-3856 in Vaginal Samples of Healthy Women after Oral Administration. Nutrients. 2020;12(8):2211.
EDWARDS JE, SCHWARTZ MM, SCHMIDT CS, SOBEL JD, NYIRJESY P, SCHODEL F et. Al. A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis-A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial. Clinial Infectious Diseases, 2018. 66(12): 1920-1932.
Federação Brasileira das Associações de Ginecologia e Obstetrítica (FEBRASGO). (Protocolo FEBRASGO – Ginecologia, no. 24 Vaginites e Vaginoses / Comissão Nacional Especializada em Doenças Infecto-Contagiosas – 2016/2019). São Paulo, 2018.
MARTIN MAS, OLMEDO MP, HERNÁNDEZ ASM, JULIÁN JP, BARBERO ER, MARTÍN MRP et. Al. Clinical significance of candidiasis with special relevance in recurrent vulvovaginal candidiasis. Gaceta Medica de Bilbao, 2019. 116(2): 74-82.
MONDELLI, AL. Candidemia: evaluation of associated factors and sensitivity to fluconazole. Tese de doutorado da Faculdade de Medicina da Universidade Julio de Mesquita Filho. Botucatu, 2010. S.n: 105.
RUSSO R, SUPERTI F, KARADJA E, DE SETA F. Randomised clinical trial in women with Recurrent Vulvovaginal Candidiasis: Efficacy of probiotics and lactoferrin as maintenance treatment. Mycoses. 2019;62(4):328-335.
SOBEL JD, SOBEL R. Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species. Expert Opin Pharmacother. 2018;19(9):971-977.
SOBEL JD, WIESENFELD HC, MARTENS M, DANNA P, HOOTON TM, ROMPALO A, et. Al. Maintence fluconazole therapy for recurrent vulvovaginal candidiasis. New England J Med, 2004; 351(9): 876 – 873.
SUPERTI F, DE SETA F. Warding Off Recurrent Yeast and Bacterial Vaginal Infections: Lactoferrin and Lactobacilli. Microorganisms. 2020;8(1):130. Published 2020 Jan 17.
TUBELLA LM, LOPEZ T, TUBELLA J. Immunotherapy with an allergen extract of candida albicans to prevent recurrent episodes of vulvovaginal candidiasis (RVVC). Allergy: European Journal of Allergy and Clinical Immunology, 2019. 74(106): 696.
VLADAREANU R, MIHU D, MITRAN M, et al. New evidence on oral L. plantarum P17630 product in women with history of recurrent vulvovaginal candidiasis (RVVC): a randomized double-blind placebo-controlled study. Eur Rev Med Pharmacol Sci. 2018;22(1):262-267.
WOODBUM KW, CLEMENS LE, JAYNES J, JOUBERT LM, BOTHA A, HASAN N et. Al. Designed Antimicrobial Peptides for Recurrent Vulvovaginal Candidiasis Treatment. Antimicrobial Agents and Chemotherapy, 2019. 63(11): e02690-18
WU X, ZHANG S, XU X, SHEN L, XU B, QU W et. Al. RAFT-Derived Polymethacrylates as a Superior Tratment for Recurrent Vulvovaginal Candidiasis by Targeting Biotic Biofilms and Persister Cells. Frontiers in Microbiology, 2019. 10.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
This work is licensed under a Creative Commons Attribution 4.0 International License.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.
